A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

Researchers say semaglutide, the medication in Ozempic and Wegovy, may help reverse MASH, a progressive liver condition ...

Q1 2025 Earnings Call Transcript April 28, 2025 Medifast, Inc. misses on earnings expectations. Reported EPS is $-0.11 EPS, ...

Greetings, and welcome to the Medifast first quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the call over ...

Detailed price information for Post Holdings Inc (POST-N) from The Globe and Mail including charting and trades.

Q1 2025 Management View CEO Dan Chard emphasized the company's focus on the evolving weight-loss market, highlighting the ...

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and ...

A once-daily weight loss pill in late-stage trials is showing promising results. The oral GLP-1 drug from Eli Lilly is in phase three of clinical studies to determine safety and efficacy for ...

The pill, poised to revolutionize the weight loss world, may be up for FDA approval in late 2025. A daily pill to rival Ozempic is one step closer to hitting the market. Pharmaceutical giant Eli ...

Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker Eli Lilly said the first trial showed similar weight loss and diabetes ...

Ore Huiying / Bloomberg / Getty Images Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released Phase 3 trial results for its oral weight-loss drug that ...